These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 19170706)

  • 1. Bone mineral density and bone turnover in Romanian children and young adults with classical 21-hydroxylase deficiency are influenced by glucocorticoid replacement therapy.
    Zimmermann A; Sido PG; Schulze E; Al Khzouz C; Lazea C; Coldea C; Weber MM
    Clin Endocrinol (Oxf); 2009 Oct; 71(4):477-84. PubMed ID: 19170706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone mineral density, bone markers, and fractures in adult males with congenital adrenal hyperplasia.
    Falhammar H; Filipsson Nyström H; Wedell A; Brismar K; Thorén M
    Eur J Endocrinol; 2013 Mar; 168(3):331-41. PubMed ID: 23211577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of total cumulative glucocorticoid dose on bone mineral density in patients with 21-hydroxylase deficiency.
    Chakhtoura Z; Bachelot A; Samara-Boustani D; Ruiz JC; Donadille B; Dulon J; Christin-Maître S; Bouvattier C; Raux-Demay MC; Bouchard P; Carel JC; Leger J; Kuttenn F; Polak M; Touraine P;
    Eur J Endocrinol; 2008 Jun; 158(6):879-87. PubMed ID: 18390993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fractures and bone mineral density in adult women with 21-hydroxylase deficiency.
    Falhammar H; Filipsson H; Holmdahl G; Janson PO; Nordenskjöld A; Hagenfeldt K; Thorén M
    J Clin Endocrinol Metab; 2007 Dec; 92(12):4643-9. PubMed ID: 17878254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced bone mineral density and increased bone metabolism rate in young adult patients with 21-hydroxylase deficiency.
    Sciannamblo M; Russo G; Cuccato D; Chiumello G; Mora S
    J Clin Endocrinol Metab; 2006 Nov; 91(11):4453-8. PubMed ID: 16926248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone mineral density is not significantly reduced in adult patients on low-dose glucocorticoid replacement therapy.
    Koetz KR; Ventz M; Diederich S; Quinkler M
    J Clin Endocrinol Metab; 2012 Jan; 97(1):85-92. PubMed ID: 21994966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of glucocorticoid replacement therapy on growth, bone mineral density, and bone turnover markers in children with congenital adrenal hyperplasia.
    Girgis R; Winter JS
    J Clin Endocrinol Metab; 1997 Dec; 82(12):3926-9. PubMed ID: 9398689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation of Bone Mineral Parameters with Anthropometric Measurements and the Effect of Glucocorticoids on Bone Mineral Parameters in Congenital Adrenal Hyperplasia.
    Ganesh R; Suresh N; Janakiraman L; Ravikumar K
    Indian J Pediatr; 2016 Feb; 83(2):126-30. PubMed ID: 26223873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone mineral density in girls with classical congenital adrenal hyperplasia due to CYP21 deficiency.
    Elnecave RH; Kopacek C; Rigatto M; Keller Brenner J; Sisson de Castro JA
    J Pediatr Endocrinol Metab; 2008 Dec; 21(12):1155-62. PubMed ID: 19189689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone mineral density and body composition in prepubertal and adolescent patients with the classical form of 21-hydroxylase deficiency.
    Sahakitrungruang T; Wacharasindhu S; Supornsilchai V; Srivuthana S; Kingpetch K
    J Med Assoc Thai; 2008 May; 91(5):705-10. PubMed ID: 18672636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term outcome of patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
    Bachelot A; Plu-Bureau G; Thibaud E; Laborde K; Pinto G; Samara D; Nihoul-Fékété C; Kuttenn F; Polak M; Touraine P
    Horm Res; 2007; 67(6):268-76. PubMed ID: 17170529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BclI polymorphism of the glucocorticoid receptor gene is associated with increased bone resorption in patients on glucocorticoid replacement therapy.
    Koetz KR; van Rossum EF; Ventz M; Diederich S; Quinkler M
    Clin Endocrinol (Oxf); 2013 Jun; 78(6):831-7. PubMed ID: 23134110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term glucocorticoid effect on bone mineral density in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
    Ceccato F; Barbot M; Albiger N; Zilio M; De Toni P; Luisetto G; Zaninotto M; Greggio NA; Boscaro M; Scaroni C; Camozzi V
    Eur J Endocrinol; 2016 Aug; 175(2):101-6. PubMed ID: 27185866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone turnover and bone mineral density in patients with congenital adrenal hyperplasia.
    Guo CY; Weetman AP; Eastell R
    Clin Endocrinol (Oxf); 1996 Nov; 45(5):535-41. PubMed ID: 8977749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone mineral density in relation to glucocorticoid substitution therapy in adult patients with 21-hydroxylase deficiency.
    Jääskeläinen J; Voutilainen R
    Clin Endocrinol (Oxf); 1996 Dec; 45(6):707-13. PubMed ID: 9039336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of an aromatase inhibitor in children with congenital adrenal hyperplasia: Impact of anastrozole on bone mineral density and visceral adipose tissue.
    Halper A; Sanchez B; Hodges JS; Dengel DR; Petryk A; Sarafoglou K
    Clin Endocrinol (Oxf); 2019 Jul; 91(1):124-130. PubMed ID: 31070802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency: a cross-sectional study of factors involved in bone mineral density.
    de Almeida Freire PO; de Lemos-Marini SH; Maciel-Guerra AT; Morcillo AM; Matias Baptista MT; de Mello MP; Guerra G
    J Bone Miner Metab; 2003; 21(6):396-401. PubMed ID: 14586796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone Mass in Young Patients with Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency.
    Espinosa Reyes TM; Leyva González G; Domínguez Alonso E; Falhammar H
    Horm Res Paediatr; 2021; 94(1-2):1-8. PubMed ID: 34044395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-dose hydrocortisone replacement therapy is associated with improved bone remodelling balance in hypopituitary male patients.
    Behan LA; Kelleher G; Hannon MJ; Brady JJ; Rogers B; Tormey W; Smith D; Thompson CJ; McKenna MJ; Agha A
    Eur J Endocrinol; 2014 Jan; 170(1):141-50. PubMed ID: 24123094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucocorticoid replacement therapy and pharmacogenetics in Addison's disease: effects on bone.
    Løvås K; Gjesdal CG; Christensen M; Wolff AB; Almås B; Svartberg J; Fougner KJ; Syversen U; Bollerslev J; Falch JA; Hunt PJ; Chatterjee VK; Husebye ES
    Eur J Endocrinol; 2009 Jun; 160(6):993-1002. PubMed ID: 19282465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.